New daily shot could replace calcium pills for rare hormone disorder
NCT ID NCT04701203
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This Phase 3 trial tested a daily injection of TransCon PTH, a synthetic parathyroid hormone, in 84 adults with hypoparathyroidism. The goal was to see if it could help patients maintain normal blood calcium levels while reducing their need for high-dose calcium and vitamin D supplements. Participants were randomly assigned to receive either the active drug or a placebo for 26 weeks, followed by an open-label extension where everyone received the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TransCon PTH (a daily injection of parathyroid hormone)
- What this could lead to
- If successful, this could offer a more targeted treatment for hypoparathyroidism, potentially reducing or eliminating the need for high-dose calcium and vitamin D supplements.
- What could go wrong
- This is a relatively small Phase 3 trial (84 participants), and results may not apply to all patients. The treatment requires daily injections and may have side effects or not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOCRINE SYSTEM DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ascendis Pharma Investigational Site
San Francisco, California, 94143, United States
-
Ascendis Pharma Investigational Site
Chicago, Illinois, 60637, United States
-
Ascendis Pharma Investigational Site
Rochester, Minnesota, 55905, United States
-
Ascendis Pharma Investigational Site
Reno, Nevada, 89511, United States
-
Ascendis Pharma Investigational Site
New York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
Greenville, North Carolina, 27834, United States
-
Ascendis Pharma Investigational Site
Austin, Texas, 78731, United States
-
Ascendis Pharma Investigational Site
Fort Worth, Texas, 76132, United States
-
Ascendis Pharma Investigational Site
Spokane, Washington, 99204, United States
-
Ascendis Pharma Investigational Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Ascendis Pharma Investigational Site
Oakville, Ontario, L6M 1M1, Canada
-
Ascendis Pharma Investigational Site
Québec, Quebec, G1V 4G2, Canada
-
Ascendis Pharma Investigational Site
Copenhagen, Capital Region, 2100, Denmark
-
Ascendis Pharma Investigational Site
Aarhus, Central Jutland, 8200, Denmark
-
Ascendis Pharma Investigational Site
Dresden, Saxony, 01307, Germany
-
Ascendis Pharma Investigational Site
Szeged, Csongrád megye, 6720, Hungary
-
Ascendis Pharma Investigational Site
Budapest, 1083, Hungary
-
Ascendis Pharma Investigational Site
Bologna, Emilia-Romagna, 40138, Italy
-
Ascendis Pharma Investigational Site
Rome, Lazio, 00128, Italy
-
Ascendis Pharma Investigational Site
Pisa, Piacenza, 56126, Italy
-
Ascendis Pharma Investigational Site
Oslo, 0176, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Testosterone may rebuild strength after spinal cord injury — trial puts it to the test
- Childhood brain tumor survivors face hidden hormone risks years later
- Could a daily shot free teens from calcium pills?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Weekly shot could free hypoparathyroidism patients from daily pills
- Weekly shot could replace daily needles for kids with growth hormone deficiency